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Introduction
Multiple sclerosis (MS) is a chronic, immune-mediated 
inflammatory disease of the central nervous system, 
which is characterized by infiltration of immune cells, 
loss of myelin and axons, and formation of multifocal 
plaques in the brain and the spinal cord.1 MS is a com-
mon disease, with approximately 2.5 million people 
affected worldwide, most of whom are young and mid-
dle-aged adults.2 At present, a definitive cure for MS is 
lacking so that its treatment is aimed primarily at reduc-
ing symptoms and disease progression via modulation of 
the immune system.3
To date, approved first-line disease-modifying therapies 
(DMTs) for the treatment of MS include glatiramer acetate 
(GA) and two types of interferon-beta (IFN-β): IFN-β-1a 
and IFN-β-1b. Both GA and IFN-β are assumed to affect 
multiple immunological processes, but the exact mecha-
nisms underlying their beneficial effects in MS are not fully 
understood.4,5 GA and IFN-β require administration via 
subcutaneous (SC) injections, while IFN-β-1a is also 
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available as an intramuscular (IM) formulation. The dosage 
and frequency of administration differ between the four 
DMTs: GA is injected once daily, IFN-β-1b once every 
other day, SC IFN-β-1a three times a week, and IM IFN-
β-1a once a week.
GA and IFN-β have proven albeit partial efficacy in 
reducing the frequency of relapses and disease activity, 
as shown by magnetic resonance imaging.6,7 Both thera-
pies are generally safe and well-tolerated with an accept-
able side-effect profile. However, patients treated with 
DMTs may frequently experience cutaneous adverse 
events.8 These cutaneous side-effects may include local 
injection-site reactions, such as erythema, induration, 
swelling, haemorrhage, pain, and pruritus around injec-
tion sites.9,10 Next to these usually transient injection-site 
reactions, more severe and persisting cutaneous compli-
cations to DMTs may occur, such as lipoatrophy and skin 
necrosis and ulcers.11,12 Cutaneous adverse events to 
DMTs can have important clinical implications as they 
may be associated with reduced treatment adherence and 
quality of life.
The aim of this systematic review is to provide an over-
view of the frequency and the spectrum of cutaneous 
adverse reactions associated with DMTs in MS patients.
Methods
Definitions
Adverse cutaneous events to DMTs were defined as any 
localized or generalized abnormality involving the skin 
during the treatment, regardless of the assumed causality 
with the drug. DMTs included SC glatiramer acetate 
(Copaxone®, Sanofi Aventis and Teva), SC IFN-β-1a 
(Rebif®, Merck Serono), IM IFN-β-1a (Avonex®, Biogen 
Idec), and SC IFN-β-1b (Betaferon® and Betaseron®, Bayer 
Schering).
Search strategy and selection criteria
An electronic literature search was performed up to 21 May 
2011 in the MEDLINE, EMBASE, and Cochrane data-
bases, including the Cochrane Multiple Sclerosis Group 
Trials Register, using combinations of the following key-
words and/or medical subject headings (MeSH): ‘glati-
ramer acetate’, ‘interferon-beta’, ‘multiple sclerosis’, 
‘cutaneous reaction’, ‘skin’, ‘dermatology’ and ‘adverse 
event’ (Supplement 1). We also included randomized con-
trolled trials (RCTs) assessing the efficacy and safety of 
DMTs, considering that some of these trials may have had 
reported cutaneous adverse events as secondary or safety 
outcomes. Additional relevant articles were selected by 
screening the reference lists of included articles. Also, the 
manufacturers of GA and the IFN-β preparations were con-
tacted for additional references.
Two authors (DMWB, AC) independently assessed the 
articles for eligibility for inclusion. Differences between 
the authors were resolved by a consensus agreement. 
Articles were first screened for relevance according to the 
title and the abstract. The remaining articles were then full-
text assessed. Eligible for inclusion were articles describing 
any skin reaction or other dermatological symptom during 
treatment with one of the DMTs. Articles were excluded if 
they described diseases other than MS, if they did not 
describe adverse cutaneous events, or if they described 
medications other than GA or IFN-β. No limitations in lan-
guage, study design, or study date were applied. Data were 
extracted from the included articles independently by two 
authors (DMWB, AC).
Results
Literature search
Our literature search yielded 1092 articles that were screened 
for eligibility, of which 106 articles were included 
(Supplement 2). There were two cross-sectional studies 
reporting the prevalence of cutaneous adverse events during 
DMT treatment. Thirty-nine (37%) of the included articles 
were RCTs or prospective follow-up studies that described 
general incidences of localized skin reactions to DMTs 
(Table 1). The other included articles (61%) were mostly 
case reports and case series that reported a total of 106 
patients with a variety of localized and generalized cutane-
ous adverse events to DMTs (Table 2 and Table 3).
Local injection-site reactions
Incidences of local injection-site reactions were reported in 
most RCTs, but a majority of these trials used different 
definitions or did not specify their definition of local injec-
tion-site reactions. The used definitions of injection-site 
reaction in these trials included redness or erythema, swell-
ing, pain, pruritus, bruising, irritation, inflammation, or 
induration of the skin around an injection site. In some of 
the RCTs, severity of the injection-site reactions was graded 
as mild, moderate, or severe. Also, some trials mentioned 
incidences of other cutaneous events, such as skin rash, 
cutaneous necrosis, and lipoatrophy. In only a few RCTs, 
adverse skin reactions were a primary outcome.52–55
Table 1 gives an overview of the reported proportions of 
patients with injection-site reactions during DMT treat-
ment. The RCTs are heterogeneous in their applied defini-
tion of skin reactions, sample size, follow-up duration and 
the used dosage or frequency of the DMT, among others, 
making it difficult to compare directly the incidences of 
injection-site reactions. Injection-site reactions developed 
in 2–33% of patients using IM IFN-β-1a. The proportion of 
patients with injection-site reactions for SC IFN-β-1a was 
between 13% and 89%, while about 22– 96% of SC 
 at Erasmus Univ Rotterdam on August 4, 2015msj.sagepub.comDownloaded from 
Balak et al. 1707
Ta
bl
e 
1.
 S
um
m
ar
y 
of
 s
tu
di
es
 d
es
cr
ib
in
g 
in
ci
de
nc
e 
or
 p
re
va
le
nc
e 
of
 c
ut
an
eo
us
 a
dv
er
se
 e
ve
nt
s 
as
so
ci
at
ed
 w
ith
 g
la
tir
am
er
 a
ce
ta
te
 a
nd
 in
te
rf
er
on
-b
et
a 
tr
ea
tm
en
t 
fo
r 
m
ul
tip
le
 s
cl
er
os
is
.
St
ud
y
Ty
pe
 o
f s
tu
dy
N
um
be
r 
of
  
pa
tie
nt
s
Fo
llo
w
-u
p 
 
du
ra
tio
n
Tr
ea
tm
en
t
In
ci
de
nc
e 
of
  
cu
ta
ne
ou
s 
 
ad
ve
rs
e 
ev
en
ts
C
ut
an
eo
us
 a
dv
er
se
 e
ve
nt
s
M
ik
ol
 e
t 
al
 (
20
08
)1
3
R
an
do
m
iz
ed
 o
pe
n-
la
be
l 
st
ud
y
37
8
1.
8 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
7–
30
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
*
M
ec
a-
La
lla
na
 e
t 
al
 (
20
10
)1
4
Fo
llo
w
-u
p 
st
ud
y
28
1–
1.
5 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
21
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
W
ol
in
sk
y 
et
 a
l (
20
07
)1
5
R
C
T
62
7
3 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
9–
57
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Jo
hn
so
n 
et
 a
l (
19
95
)1
6
R
C
T
12
5
2 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
19
–6
4%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
K
or
cz
yn
 e
t 
al
 (
19
96
)1
7
D
at
ab
as
e 
of
 m
ul
tip
le
 R
C
T
 
da
ta
85
7
—
G
A
 (
di
ffe
re
nt
 d
os
ag
es
)
14
–5
4%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Z
w
ib
el
 (
20
06
)1
8
O
pe
n-
la
be
l s
tu
dy
80
5
3.
5 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
54
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
C
om
i e
t 
al
 (
20
11
)1
9
R
C
T
58
6
56
9
1 
ye
ar
G
A
 2
0 
m
g 
da
ily
G
A
 4
0 
m
g 
da
ily
56
%
58
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
M
ill
er
 e
t 
al
 (
20
08
)2
0
O
pe
n-
la
be
l s
tu
dy
46
12
 y
ea
rs
G
A
 2
0 
m
g 
da
ily
≥ 
50
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Li
po
at
ro
ph
y 
(n
=
4)
O
’C
on
no
r 
et
 a
l (
20
09
)2
1
Ph
as
e 
III
 R
C
T
44
5
2–
3.
5 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
58
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Jo
hn
so
n 
et
 a
l (
19
98
)2
2
Ex
te
ns
io
n 
to
 R
C
T
12
5
2.
5 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
66
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Fl
ec
ht
er
 e
t 
al
 (
20
02
)2
3
O
pe
n-
la
be
l s
tu
dy
38
2 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
G
A
 2
0 
m
g 
eo
d
70
%
67
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Li
po
at
ro
ph
y 
(n
=
3 
in
 d
ai
ly
 
gr
ou
p)
Fl
ec
ht
er
 e
t 
al
 (
20
02
)2
4
O
pe
n-
la
be
l s
tu
dy
68
1-
2 
ye
ar
s
G
A
 2
0 
m
g 
eo
d
61
%
7%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
as
h
D
eb
ou
ve
ri
e 
et
 a
l (
20
07
)2
5
O
pe
n-
la
be
l s
tu
dy
20
5
4 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
81
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Jo
hn
so
n 
et
 a
l (
19
95
)1
6
R
C
T
12
5
2 
ye
ar
s
G
A
 2
0 
m
g 
da
ily
90
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Eu
ro
pe
an
 S
tu
dy
 g
ro
up
 o
n 
IF
N
-β
-1
b 
in
 
se
co
nd
ar
y 
pr
og
re
ss
iv
e 
M
S 
(1
99
8)
26
R
C
T
36
0
2–
3 
ye
ar
s
IF
N
-β
-1
b 
25
0 
ug
 e
od
5% 21
%
44
%
50
%
N
ec
ro
si
s;
 
R
as
h
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
;
In
fla
m
m
at
io
n
G
ot
te
sm
an
 e
t 
al
 (
20
06
)2
7
O
pe
n-
la
be
l s
tu
dy
22
0.
4 
ye
ar
s
IF
N
-β
-1
b 
50
0 
ug
 e
od
22
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
as
h/
ur
tic
ar
ia
 (
n=
1)
Br
oc
he
t 
et
 a
l (
20
06
)2
8
R
C
T
29
4
0.
1 
ye
ar
s
IF
N
-β
-1
b 
(a
ut
o-
in
je
ct
or
)
IF
N
-β
-1
b
24
%
36
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
D
ur
el
li 
et
 a
l (
20
02
)2
9
R
C
T
94
2 
ye
ar
s
IF
N
-β
-1
b 
25
0 
ug
 e
od
37
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
N
ei
lle
y 
et
 a
l (
19
96
)3
0
O
pe
n 
la
be
l s
tu
dy
72
—
IF
N
-β
-1
b 
50
0 
ug
 e
od
42
%
Sk
in
 r
ea
ct
io
ns
K
ap
po
s 
et
 a
l (
20
06
)3
1
R
C
T
29
2
2 
ye
ar
s
IF
N
-β
-1
b 
25
0 
ug
 e
od
48
%
11
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
as
h
T
he
 IF
N
B 
M
ul
tip
le
 S
cl
er
os
is
 S
tu
dy
 G
ro
up
 
an
d 
th
e 
U
ni
ve
rs
ity
 o
f B
ri
tis
h 
C
ol
um
bi
a 
M
S/
M
R
I A
na
ly
si
s 
G
ro
up
 (
19
96
)3
2
R
C
T
12
4
3 
ye
ar
s
IF
N
-β
-1
b 
50
0 
ug
 e
od
46
–6
6%
4%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 n
ec
ro
si
s
(C
on
tin
ue
d)
 at Erasmus Univ Rotterdam on August 4, 2015msj.sagepub.comDownloaded from 
1708 Multiple Sclerosis Journal 18(12)
St
ud
y
Ty
pe
 o
f s
tu
dy
N
um
be
r 
of
  
pa
tie
nt
s
Fo
llo
w
-u
p 
 
du
ra
tio
n
Tr
ea
tm
en
t
In
ci
de
nc
e 
of
  
cu
ta
ne
ou
s 
 
ad
ve
rs
e 
ev
en
ts
C
ut
an
eo
us
 a
dv
er
se
 e
ve
nt
s
H
ur
w
itz
 e
t 
al
 (
20
08
)3
3
R
an
do
m
is
ed
 p
ilo
t 
st
ud
y
33 38
0.
2 
ye
ar
s
IF
N
-β
-1
b 
50
0 
ug
 e
od
IF
N
-β
-1
b 
25
0 
ug
 e
od
58
%
66
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
as
h 
(6
–1
1%
)
O
’C
on
no
r 
et
 a
l (
20
09
)2
1
R
C
T
88
8
88
7
2–
3.
5 
ye
ar
s
IF
N
-β
-1
b 
25
0 
ug
 e
od
IF
N
-β
-1
b 
50
0 
ug
 e
od
48
%
55
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
K
ap
po
s 
et
 a
l (
20
09
)3
4
Ex
te
ns
io
n 
to
 R
C
T
46
8
5 
ye
ar
s
IF
N
-β
-1
b 
25
0 
ug
 e
od
54
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Ba
um
 e
t 
al
 (
20
06
)1
3
R
C
T
15
1
14
5
0.
5 
ye
ar
s
IF
N
-β
-1
b 
(w
ith
 m
an
ni
to
l)
IF
N
-β
-1
b 
(w
ith
 g
lu
co
se
)
92
%
96
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
io
 e
t 
al
 (
19
98
)3
5
Pr
os
pe
ct
iv
e 
fo
llo
w
-u
p 
st
ud
y
95
1 
ye
ar
IF
N
-β
-1
b 
50
0 
ug
 e
od
70
%
Sk
in
 r
ea
ct
io
ns
M
on
ta
lb
an
 e
t 
al
 (
20
09
)3
6
R
C
T
36
2 
ye
ar
s
IF
N
-β
-1
b 
25
0 
ug
 e
od
78
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Fl
ec
ht
er
 e
t 
al
 (
20
02
)2
4
O
pe
n-
la
be
l s
tu
dy
20
2 
ye
ar
s
IF
N
-β
-1
b 
25
0 
ug
 e
od
80
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
ed
er
 e
t 
al
 (
20
10
)3
7
C
ro
ss
-s
ec
tio
na
l f
ol
lo
w
-u
p 
st
ud
y 
of
 R
C
T
69
—
IF
N
-β
-1
b 
25
0 
ug
 e
od
81
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
C
oh
en
 e
t 
al
 (
20
10
)7
4
R
C
T
43
1
1 
ye
ar
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
0.
5%
Ba
sa
l-c
el
l c
ar
ci
no
m
a
Sq
ua
m
ou
s-
ce
ll 
ca
rc
in
om
a
Ja
co
bs
 e
t 
al
 (
19
96
)3
8
R
C
T
15
8
2 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
2%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
H
av
rd
ov
a 
et
 a
l (
20
09
)3
9
Ex
te
ns
io
n 
to
 R
C
T
60
3 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g.
w
ee
k
3%
Er
yt
he
m
at
ou
s 
ra
sh
G
he
zz
i e
t 
al
 (
20
07
)4
0
Fo
llo
w
 u
p 
st
ud
y
52
1.
8 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
4%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Sc
hw
id
 e
t 
al
 (
20
05
)4
1
Ex
te
ns
io
n 
to
 R
C
T
22
3
27
2
0.
6 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
33
%
51
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Sa
nd
be
rg
-W
ol
lh
ei
m
 e
t 
al
 (
20
05
)4
2
R
C
T
33
8
33
9
1.
2 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
30
%
75
%
M
ild
 in
je
ct
io
n-
si
te
 r
ea
ct
io
ns
 
(m
od
er
at
e 
5%
)
M
ild
 in
je
ct
io
n-
si
te
 r
ea
ct
io
ns
 
(m
od
er
at
e 
15
%
; s
ev
er
e 
1%
)
H
er
nd
on
 e
t 
al
 (
20
05
)4
3
Ex
te
ns
io
n 
to
 R
C
T
38
2
6 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
35
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
D
ur
el
li 
et
 a
l (
20
02
)2
9
R
C
T
88
2 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
8%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Le
ar
y 
et
 a
l (
20
03
)4
4
R
C
T
15
2 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
IM
 IF
N
-β
-1
a 
60
 u
g/
w
ee
k
7% 15
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Pa
ni
tc
h 
et
 a
l (
20
02
)4
5
R
C
T
33
7
0.
5 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
28
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Ph
ill
ip
s 
et
 a
l (
20
04
)4
6
O
pe
n-
la
be
l s
tu
dy
15
3
2 
ye
ar
s
IM
 IF
N
-β
-1
a 
30
 u
g/
w
ee
k
31
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
G
io
va
nn
on
i e
t 
al
 (
20
09
)1
4
O
pe
n-
la
be
l s
tu
dy
26
0
1.
8 
ye
ar
s
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
 
(R
eb
if 
ne
w
 fo
rm
ul
at
io
n)
31
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
as
h 
(n
=
16
)
M
ik
ol
 e
t 
al
 (
20
08
)1
3
R
an
do
m
iz
ed
 o
pe
n-
la
be
l 
st
ud
y
38
1
1.
8 
ye
ar
s
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
41
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
as
h 
(n
=
28
)
Fr
ee
dm
an
 e
t 
al
 (
20
05
)4
7
R
C
T
87 88
0.
9 
ye
ar
s
SC
 IF
N
-β
-1
a 
22
 u
g 
T
IW
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
13
%
26
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
Ta
bl
e 
1.
 (
C
on
tin
ue
d)
 at Erasmus Univ Rotterdam on August 4, 2015msj.sagepub.comDownloaded from 
Balak et al. 1709
St
ud
y
Ty
pe
 o
f s
tu
dy
N
um
be
r 
of
  
pa
tie
nt
s
Fo
llo
w
-u
p 
 
du
ra
tio
n
Tr
ea
tm
en
t
In
ci
de
nc
e 
of
  
cu
ta
ne
ou
s 
 
ad
ve
rs
e 
ev
en
ts
C
ut
an
eo
us
 a
dv
er
se
 e
ve
nt
s
A
nd
er
se
n 
et
 a
l (
20
04
)4
8
R
C
T
18
6
3 
ye
ar
s
SC
 IF
N
-β
-1
a 
22
 u
g/
w
ee
k
31
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
O
ge
r 
et
 a
l (
20
05
)4
9
R
C
T
87 85
2 
ye
ar
s
SC
 IF
N
-β
-1
a 
22
 u
g 
T
IW
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
66
%
66
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
A
bs
ce
ss
 a
t 
in
je
ct
io
n 
si
te
 (
n=
1)
Pa
ni
tc
h 
et
 a
l 2
00
24
5
R
C
T
33
9
0.
5 
ye
ar
s
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
89
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
R
as
h 
(n
=
56
)
PR
IS
M
S 
st
ud
y 
gr
ou
p 
(1
99
8)
50
R
C
T
18
9
18
4
2 
ye
ar
s
SC
 IF
N
-β
-1
a 
22
 u
g 
T
IW
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
39
%
40
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
D
ev
on
sh
ir
e 
et
 a
l (
20
10
)1
6
Pr
os
pe
ct
iv
e 
fo
llo
w
-u
p 
st
ud
y
10
2
0.
2 
ye
ar
s
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
 
(R
eb
ije
ct
 II
)
76
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
G
ol
d 
et
 a
l (
20
05
)5
1
R
C
T
18
9
18
4
4 
ye
ar
s
SC
 IF
N
-β
-1
a 
22
 u
g 
T
IW
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
73
%
71
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
 (
sk
in
 
ne
cr
os
is
: n
=
7)
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
 (
sk
in
 
ne
cr
os
is
: n
=
13
)
Lu
ga
re
si
 e
t 
al
 (
20
08
)1
5
Pr
os
pe
ct
iv
e 
fo
llo
w
-u
p 
st
ud
y
76
1 
ye
ar
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
 
(R
eb
ije
ct
)
79
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
 (
n=
50
 
pe
rs
is
te
d)
Pa
ni
tc
h 
et
 a
l (
20
02
)4
5
R
C
T
33
9
0.
5 
ye
ar
s
SC
 IF
N
-β
-1
a 
44
 u
g 
T
IW
83
%
In
je
ct
io
n-
si
te
 r
ea
ct
io
ns
*I
nj
ec
tio
n 
si
te
 r
ea
ct
io
ns
 in
cl
ud
e 
er
yt
he
m
a, 
sw
el
lin
g, 
oe
de
m
a, 
pa
in
, p
ru
ri
tu
s, 
br
ui
si
ng
, h
ae
m
or
rh
ag
e,
 ir
ri
ta
tio
n,
 a
nd
 in
du
ra
tio
n.
A
bb
re
vi
at
io
ns
: e
od
, e
ve
ry
 o
th
er
 d
ay
; G
A
, g
la
tir
am
er
 a
ce
ta
te
; I
FN
-β
, i
nt
er
fe
ro
n 
be
ta
; I
M
, i
nt
ra
m
us
cu
la
r; 
N
A
, n
ot
 a
pp
lic
ab
le
; R
C
T,
 r
an
do
m
iz
ed
 c
on
tr
ol
le
d 
tr
ia
l; 
R
R
M
S, 
re
la
ps
in
g 
re
m
itt
in
g 
m
ul
tip
le
 s
cl
er
os
is
; S
C
, 
su
bc
ut
an
eo
us
; T
IW
, t
hr
ee
 t
im
es
 a
 w
ee
k.
Ta
bl
e 
1.
 (
C
on
tin
ue
d)
 at Erasmus Univ Rotterdam on August 4, 2015msj.sagepub.comDownloaded from 
1710 Multiple Sclerosis Journal 18(12)
Ta
bl
e 
2.
 C
as
e-
re
po
rt
s 
an
d 
ca
se
-s
er
ie
s 
de
sc
ri
bi
ng
 c
ut
an
eo
us
 r
ea
ct
io
ns
 t
o 
gl
at
ir
am
er
 a
ce
ta
te
 a
nd
 in
te
rf
er
on
-b
et
a 
tr
ea
tm
en
t 
of
 m
ul
tip
le
 s
cl
er
os
is
.
Ty
pe
 o
f s
ki
n 
le
si
on
To
ta
l n
o.
 o
f  
ca
se
 r
ep
or
ts
To
ta
l n
o.
 o
f 
pa
tie
nt
s
H
is
to
lo
gy
  
ob
ta
in
ed
 (
no
.  
of
 p
at
ie
nt
s)
D
M
T
Im
pl
ic
at
io
ns
 fo
r 
tr
ea
tm
en
t
 
G
A
SC
 IF
N
-β
-1
a
IM
 IF
N
-β
-1
a
IF
N
-β
-1
b
St
op
pe
d
C
on
tin
ue
d
U
nk
no
w
n
Li
po
at
ro
ph
y
8
30
20
28
1
–
1
29
1
–
C
ut
an
eo
us
 u
lc
er
s
4
20
20
–
–
–
20
4
2
14
C
ut
an
eo
us
 n
ec
ro
si
s
12
15
9
 2
1
–
12
6
4
 5
Pa
nn
ic
ul
iti
s
4
5
5
–
2
–
3
2
3
–
U
rt
ic
ar
ia
3
4
0
–
–
3
1
4
–
–
C
ut
an
eo
us
 v
as
cu
lit
is
4
4
3
 1
2
–
2
4
–
–
Em
bo
lia
 c
ut
is
 m
ed
ic
am
en
to
sa
4
4
3
 3
1
–
–
–
3
1
Lu
pu
s-
lik
e 
re
ac
tio
ns
2
3
3
–
–
–
3
1
–
2
Ps
or
ia
si
s
3
3
1
–
1
–
2
1
1
1
A
lle
rg
ic
 lo
ca
l r
ea
ct
io
ns
1
3
0
 3
–
–
–
1
2
–
Sy
st
em
ic
 L
.E
.
1
1
0
–
1
–
–
1
–
–
C
ut
an
eo
us
 L
E
1
1
0
–
–
1
–
1
–
–
Fi
xe
d 
dr
ug
 e
ru
pt
io
n
1
1
1
–
–
–
1
1
–
–
L.
E.
 p
ro
fu
nd
us
1
1
1
–
–
–
1
1
–
–
Sc
le
ro
m
yx
ed
em
a
1
1
1
–
–
1
–
1
–
–
C
ut
an
eo
us
 m
uc
in
os
es
1
1
1
–
–
–
1
1
–
–
G
ra
nu
lo
m
at
ou
s 
de
rm
at
iti
s
1
1
1
–
–
–
1
1
–
–
C
ut
an
eo
us
 T
 c
el
l l
ym
ph
om
a
1
1
1
 1
–
–
–
–
1
–
C
ut
an
eo
us
 T
 c
el
l p
se
ud
ol
ym
ph
om
a
1
1
1
 1
–
–
–
–
1
–
C
al
ci
fie
d 
no
du
li
1
1
1
–
1
–
–
–
1
–
D
er
m
at
om
yo
si
tis
1
1
1
–
–
1
 1
 1
–
–
Su
bc
ut
an
eo
us
 in
fil
tr
at
io
n
1
1
1
–
–
–
 1
–
1
–
Er
yt
he
m
a 
el
ev
at
um
 d
iu
tin
um
1
1
1
–
1
–
–
 1
–
–
Er
yt
he
m
a 
no
do
su
m
1
1
1
 1
–
–
–
–
1
–
N
on
sc
ar
ri
ng
 a
lo
pe
ci
a
1
1
0
 1
–
–
–
 1
–
–
V
iti
lig
o
1
1
0
–
1
–
–
 1
–
–
A
bb
re
vi
at
io
ns
: D
M
T,
 d
is
ea
se
-m
od
ify
in
g 
th
er
ap
y; 
G
A
, g
la
tir
am
er
 a
ce
ta
te
; I
FN
-β
, i
nt
er
fe
ro
n-
be
ta
; L
.E
., 
lu
pu
s 
er
yt
he
m
at
os
us
; S
C
, s
ub
cu
ta
ne
ou
s.
 at Erasmus Univ Rotterdam on August 4, 2015msj.sagepub.comDownloaded from 
Balak et al. 1711
IFN-β-1b patients and 7–90% of GA patients had devel-
oped local injection-site reactions.
Lipoatrophy
Lipoatrophy was a frequently reported adverse skin reaction, 
mostly in patients treated with GA. A prospective follow-up 
study reported that 4 (15%) out of 27 patients treated with 
GA had developed localized lipoatrophy at sites of injection 
after 3 years of treatment.12 A larger, cross-sectional study 
from a single outpatient MS clinic in Canada found that 45% 
(34 out of 76) of patients with GA therapy had developed 
lipoatrophy after, on average, 2.4 years of treatment.56 
Another Canadian study assessed 100 consecutive patients 
receiving MS treatment, and reported 9 (64%) out of 14 
patients treated with GA who had developed lipoatrophy.57
There were multiple case reports and case series describ-
ing a total of 30 patients who developed lipoatrophy several 
years after initiation of GA (Table 2). In some of these cases, 
lipoatrophy persisted or continued to enlarge despite cessa-
tion of GA.58,59 There were two documented cases published 
in which lipoatrophy was associated with SC IFN-β-1a and 
IFN-β-1b, respectively.60,61 Some case reports reported a 
combination of panniculitis and lipoatrophy in association 
with GA or with IFN-β-1b.57,60,62
Cutaneous ulcers and necrosis
Cutaneous ulcers were mainly described in patients who 
were treated with IFN-β-1b. A study by Webster and col-
leagues reported 8 (2%) out of 400 patients treated with 
IFN-β-1b who had developed skin ulcers.63 Elgart and col-
leagues described 6 (6%) out of 100 consecutive patients 
on IFN-β-1b therapy with ulcers.64
In addition, several published case reports reported an 
association between IFN-β-1b therapy and the develop-
ment of cutaneous ulcers and skin necrosis at multiple 
injection sites.65–75 GA and SC IFN-β-1a have also been 
linked to skin ulcerations with skin necrosis at injection 
sites in two case reports.75,76
Embolia cutis medicamentosa, also known as Nicolau’s 
syndrome, was described in four patients.77–80 Three of these 
patients were treated with GA, and one with SC IFN-β-1a. 
All patients experienced acute intense pain immediately 
after drug injection. The clinical features consisted of dark-
red skin lesions with central necrosis and lightning-like 
extensions. The cause of Nicolau’s syndrome is most prob-
ably related to the injection rather than the injected drug.79 
Consistent with this notion, all four patients could continue 
their treatment without complications of DMT treatment.
Immune-mediated cutaneous adverse events
There were multiple reports of various immune-mediated and 
inflammatory dermatological diseases in association with DMTs. 
Psoriasis, a common immune-mediated inflammatory skin dis-
ease, has been reported with IFN-β treatment in three 
patients.63,81,82 There were four case reports of cutaneous vasculi-
tis as adverse cutaneous events to GA, SC IFN-β-1a, and IFN-
β-1b (two patients).83–86 Erythema elevatum diutinum, a 
cutaneous type of vasculitis, was described in a patient treated 
with SC IFN-β-1a.87 Panniculitis was described in three patients 
treated with IFN-β-1b and in two patients with SC IFN-β-1a.88–91 
Nousari and colleagues described the development of cutaneous 
subacute lupus erythematosus in association with IM IFN-β-1a92. 
Lupus-like reactions were described in four MS patients who 
were treated with IFN-β-1b.93–95 Cutaneous events with an 
inflammatory pathogenesis that were described only once in 
association with DMTs include dermatomyositis, erythema 
nodosum, scleromyxedema, lupus erythematosus profundus, 
vitiligo, and Jessner-Kanof benign lymphocytic infiltrate.96–101
Allergic reactions
Allergic type 1 hypersensitivity reactions were reported 
mainly for GA. Three patients were reported who 
Table 3. The spectrum of cutaneous adverse reactions associated with the different disease-modifying treatments .
SC glatiramer acetate SC IFN-β-1a IM IFN-β-1a SC IFN-β-1b
Lipoatrophy Lipoatrophy Cutaneous SLE Lipoatrophy
Cutaneous necrosis Cutaneous necrosis Urticaria Cutaneous ulcers
Panniculitis Panniculitis Drug eruption Cutaneous necrosis
Cutaneous vasculitis Cutaneous vasculitis LEP Panniculitis
Embolia cutis medicamentosa Embolia cutis medicamentosa Scleromyxedema Cutaneous vasculitis
Cutaneous T cell lymphoma Psoriasis Cutaneous SLE/LEP
Cutaneous T cell pseudolymphoma Calcified noduli Lupus-like reactions
Erythema nodosum Dermatomyositis Psoriasis
Alopecia Erythema elevatum diutinum Granulomatous dermatitis
 Vitiligo Subcutaneous infiltration
 Fixed drug eruption
Abbreviations: SC, subcutaneous; IFN, interferon; IM, intramuscular; SLE, systemic lupus erythematosus; LEP, Lupus erythematosus profundus.
 at Erasmus Univ Rotterdam on August 4, 2015msj.sagepub.comDownloaded from 
1712 Multiple Sclerosis Journal 18(12)
developed pruritic wheals or erythema and itchy hives in 
response to GA injections.102 One of these patients was sus-
pected of an IgE-mediated reaction to GA. There was a 
report of exacerbation of cholinergic urticaria during GA 
treatment.103 Severe systemic allergic and anaphylactic 
reactions were reported in association with GA as well.104,105 
Alava and colleagues described an atopic patient who 
developed allergic reactions to GA, and subsequently urti-
caria to IM IFN-β-1a.106 Also, several reports were pub-
lished on the development of widespread urticaria and 
angioedema to IM IFN-β-1a.107–109 Dimov and co-workers 
described a severe reaction with hives and angioedema of 
the extremities following IM IFN-β-1a injections.110 Brown 
and colleagues described an urticarial reaction in a patient 
treated with IFN-β-1b.111
Cutaneous malignancies
One case report described the association between GA and 
a cutaneous lymphoma in a 33-year-old female MS patient 
who had developed a CD30-positive, primary, cutaneous, 
anaplastic large-cell lymphoma after four months of GA 
treatment.112 After surgical excision and radiotherapy, 
remission was achieved and GA could be successfully con-
tinued in this patient. Skin cancers were reported several 
times in association with DMTs. In a RCT comparing the 
efficacy and safety of fingolimod to that of IM IFN-β-1a, 
there were reports of a squamous cell carcinoma and a basal 
cell carcinoma in two patients treated with IM IFN-β-1b 
compared to five basal cell carcinomas and three melano-
mas among those treated with fingolimod.113 Fruland and 
colleagues described a squamous cell carcinoma in a 
47-year-old male MS patient who was treated with 
IFN-β-1b.114
Other cutaneous adverse events
Several skin reactions associated with DMTs were 
described only once or twice. Tai and Tam reported a fixed 
drug eruption associated with IFN-β-1b treatment, pre-
senting as multiple erythematous plaques at non-injection 
sites.115 Another case report described a widespread 
macolopapular rash following IM IFN-β-1a injections 
with a positive prick test to IFN-β-1a.116 Other less fre-
quently occurring cutaneous adverse events reported 
among MS patients receiving DMTs were granulomatous 
dermatitis, subcutaneous infiltrate, calcified subcutaneous 
nodule and alopecia.117–120
Discussion
We performed a systematic review of the literature to 
describe the incidence and the clinical spectrum of cutane-
ous adverse events in patients treated with DMTs for MS. 
Incidences of cutaneous adverse events were reported in 
several RCTs and a few prospective follow-up studies. 
Available data from these studies showed that a substantial 
proportion of MS patients receiving DMTs developed local 
injection-site reactions during their treatment. Up to 
approximately 90% of patients treated with GA and SC 
IFN-β had developed local skin reactions. The incidence 
among patients treated with IM IFN-β-1a appeared to be 
lower, with up to 33% of these patients developing skin 
reactions. There were no major differences in the occur-
rence of injection-site reactions between the different dos-
ages of the DMTs. Next to the local injection-site skin 
reactions, there were many case reports and case series of 
more severe, generalized and sometimes persisting cutane-
ous adverse events described in association with DMTs. 
Frequently reported cutaneous adverse events to DMTs in 
MS patients were lipoatrophy, skin necrosis and ulcers. In 
addition, a wide variety of dermatological diseases associ-
ated with DMTs were described, including various immune-
mediated inflammatory skin diseases, such as psoriasis, 
vasculitis, and lupus-like reactions. Most of these dermato-
logical reactions were rare and described only once. In sev-
eral cases, cessation of DMT or switching to another DMT 
was required.
Several limitations need to be considered. Firstly, a sys-
tematic review of adverse events is challenging with regard 
to the literature search. We cannot exclude the possibility 
that relevant articles were missed in our literature search. 
Secondly, definitions of skin reactions were not uniform 
among the included RCTs, making it difficult to compare 
these or to calculate a risk estimate for the incidence of skin 
reactions. Thirdly, RCTs in general measure only common, 
short-term adverse events. There were only a few observa-
tional (cross-sectional and cohort) studies available that 
assessed cutaneous adverse events in MS patients treated 
with DMTs. Case reports do provide information on the 
occurrence of less frequent side-effects, but a definitive 
causal relationship with the DMT is not always clear. 
Furthermore, there were only few studies that assessed 
cutaneous adverse events as a primary outcome.
Several mechanisms have been postulated by which 
DMTs induce skin reactions. Most theories focus on 
immune-mediated mechanisms, including local inflamma-
tory reactions, IgE-mediated reactions, delayed hypersensi-
tivity reactions and other immune reactions.121 Buttmann 
and colleagues showed that SC IFN-β is able to induce 
local chemokine production, which can lead to inflamma-
tory skin reactions.122 Consistent with this, several of the 
reported cutaneous adverse events have an immune-medi-
ated pathogenesis, such as psoriasis and vasculitis. 
Mechanical injury due to injections seems less likely to 
play an important role in the development of these cutane-
ous adverse events. Embolia cutis medicamentosa, how-
ever, seems to be the only exception as it is associated with 
the injection itself rather than with the drug injected.79,121
Based upon the results of our literature review lipoatro-
phy seemed more frequently reported in association with 
GA in comparison to the other DMTs. A majority of the 
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cases with lipoatrophy were linked to GA. However, there 
were reports of lipoatrophy in two patients treated with SC 
IFN-β-1a and IFN-β-1b, respectively. By contrast, cutane-
ous necrosis was reported solely in relationship to SC IFN-
β-1b. For the other types of cutaneous adverse events, there 
was no clear relationship with a specific DMT. Still, the 
evidence for the occurrence of specific adverse events asso-
ciated with a specific DMT is limited given that prospective 
studies designed to assess the incidences of cutaneous 
adverse events with each DMT are lacking.
Several immune-mediated cutaneous adverse events 
were described in association with DMT, including associ-
ations with psoriasis, lupus erythematosus and dermatomy-
ositis. A definite causal role of the DMT was not clearly 
established in most of these case-reports, making it unclear 
whether the associations with immune-mediated cutaneous 
adverse events are truly attributable to the DMT. Somani 
and colleagues have provided experimental evidence sup-
porting a causal role of interferon treatment in the develop-
ment of dermatomyositis as a cutaneous adverse event to 
DMT.96 Still, the reported immune-mediated cutaneous 
events may be related to MS itself rather than to the DMT, 
considering the described associations between MS and 
other immune-mediated diseases such as inflammatory 
bowel disease and bullous pemphigoid.123,124 Alternatively, 
treatment with DMT may pose an additional increased risk 
to develop immune-mediated cutaneous adverse events in 
patients with multiple sclerosis.
Cutaneous malignancies associated with DMT were 
reported in a few RCTs and case reports, but DMT-use does 
not seem to be associated with an increased risk of skin 
cancer. A French cohort study did not find an increased risk 
of skin cancer among MS patients treated with DMT.125 
Similarly, a recent analysis of data from several RCTs and 
data from a global drug safety database showed that long-
term treatment with SC IFN-β-1a was not associated with 
malignancies, including melanoma skin cancer. However, 
non-melanoma skin cancers were not included in these 
analyses.126
It is interesting to compare the incidence of cutaneous 
adverse events associated with DMTs to that of injectable 
therapies for other chronic diseases, even though direct 
comparisons are lacking. Studies in patients with inflam-
matory bowel disease who were treated with subcutaneous 
anti-tumour necrosis factor alpha inhibitors demonstrated a 
relatively high incidence of skin reactions and a broad 
spectrum of cutaneous adverse events.127 Similar high inci-
dences were reported for rheumatoid arthritis patients 
treated with daily subcutaneous injections of a interleu-
kin-1 receptor antagonist.128
The occurrence of skin reactions may lead to cessation of 
the DMT or switching to another type DMT. Given that der-
matologists have experience in the diagnosis and treatment of 
immune-mediated inflammatory skin diseases, they may help 
in assessing and treating the skin reactions induced by DMTs 
without the necessity of stopping or switching the DMT.
Future research should aim at assessing the determinants 
of cutaneous adverse events in long-term treatment with 
DMT in large observational studies, such as cumulative 
injections, anatomical site correlations and dose depend-
ency. Furthermore, it would be of interest to assess if there 
is a correlation between the occurrence of skin reactions 
and the efficacy of the DMT. Another interesting research 
question for future studies is whether cutaneous reactions 
to DMT are associated with a decrease in treatment adher-
ence. In a large multicentre observational study among 
2648 patients, injection-related problems were a commonly 
cited reason for non-adherence.55 Furthermore, it would be 
relevant to assess the impact of skin reactions on patient 
quality of life. If there is a significant clinical impact, it 
would be helpful to assess interventions to prevent or 
reduce the onset of cutaneous adverse events. Attempts 
have been made already to prevent local skin reactions via 
oral antihistamines and warm compresses.129,130
In conclusion, this systematic review shows that DMTs 
in MS are frequently associated with local injection-site 
reactions and a wide range of other cutaneous adverse 
events.
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